With close monitoring, the discontinuation of eculizumab is safe in the majority of patients with atypical hemolytic uremic syndrome. Discontinuation of the terminal complement inhibitor eculizumab in ...

AstraZeneca’s Ultomiris met its primary endpoint in the Phase III I CAN trial for IgA nephropathy, significantly reducing proteinuria at 34 weeks. The result marks the first late-stage success for the ...

Researchers analyzed BTH definition, frequency, and severity across phase 3 clinical trials with terminal complement inhibitors (ravulizumab and crovalimab) and upstream complement inhibitors ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

Novartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta.